|
|
|
|
|
|
|
M T W Thu F |
|
27 August, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
A new report from HELP Chairman Sen. Bill Cassidy (R-LA) details the extent to which three makers of the abortion pill mifepristone have followed federal guidelines about how the drug can be dispensed and to whom. One of the conclusions is that prescribers, especially online ones, may be able to skirt some of the requirements. The report also suggests that rule changes made under the Obama administration have resulted in less transparency around non-fatal safety cases.
Still, the report lacked a smoking gun about the broader safety of mifepristone. While data suggests the drug is safe, conservatives have sought to limit its use. The FDA has said it's reviewing mifepristone's safety, though some lawmakers have grown frustrated that it's taken so long. |
|
|
|
Max Bayer |
Senior Reporter, Endpoints News
|
|
|
|
|
|
|
by Nicole DeFeudis
|
The pharma industry has suffered a definitive loss in its legal battle against Medicare negotiations. The Fifth Circuit Court of Appeals on Wednesday rejecteda... | |
|
|
|
|
|
|
by Max Bayer
|
Nearly two months into a federal pilot program aimed at expanding access to weight loss drugs for seniors, uptake data and reported benefits are beginning... | |
|
|
|
 |
|
|
|
by Reynald Castaneda
|
For Akeso CEO Michelle Xia, the intense spotlight on her company and its PD-1xVEGF bispecific ivonescimab still feels new, despite several years in the headlines... | |
|
|
|
|
|
|
|
|
by Kyle LaHucik
|
As its world-leading GLP-1 earns more than any other medicine— and its market cap eclipses all other healthcare companies — Eli Lilly has decided... | |
|
|
|
|
|
|
by Ayisha Sharma
|
Generate:Biomedicines shared Phase 1 data for its respiratory disease drug as part of the European Respiratory Society's (ERS) annual meeting after posters were prematurely released... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news about Takeda China and ProFound. Moderna's $2B offering: The mRNA biotech will offer convertible senior notes
for the "flexibility to invest" in growing... | |
|
|
|
|
